Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180025/S016

MANTA Vascular Closure Device

Teleflex Medical LLC · Decision date Apr 23, 2026

FDA DECISIONP180025/S016

What did the FDA decide?

FDA records P180025/S016 as a supplement to PMA P180025, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 23, 2026.

FDA approval order statement

a change to the microbiology test laboratory location for the MANTA product family
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Apr 23, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P180025/S016
Regulatory pathway
PMA supplement
Product code
MGB
Decision code
OK30
Decision date
Apr 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, hemostasis, vascular.

Product code
MGB
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P180025/S014 · Related supplement

    MANTA Vascular Closure Device; MANTA Vascular Closure Device, 18F; MANTA Vascular Closure Device, 14F; MANTA SF Depth L

  2. P180025/S015 · Related supplement

    MANTA Vascular Closure Device

  3. P180025/S016 received

    Application receipt date recorded by FDA.

  4. P180025/S016 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P180025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180025

Product / regulatory recordCompanyPathwayDecision dateSource
Teleflex Medical LLCPMA supplementAug 5, 2025FDA
Teleflex Medical LLCPMA supplementFeb 27, 2026FDA

Explore the linked device profile

Other records with product code MGB

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Teleflex Medical LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3015 Carrington Mill Blvd., Morrisville, NC, 27560

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records